| ²é¿´: 742 | »Ø¸´: 6 | |||
[½»Á÷]
ÎÄÏ×·ÖÏí | ÃâÒßµ÷¿ØÁªºÏÉñ¾µ÷¿Ø£¬IFÓÉ11.4Ìá¸ßΪ25.5
|
|||
|
ÃâÒßµ÷¿ØÊÇÖ¸»úÌå¶ÔÍâ½ç´Ì¼¤×ö³öµÄÃâÒß·´Ó¦¹ý³ÌÖУ¬Í¨¹ý¸÷ÖÖµ÷¿Ø»úÖÆÀ´±£³ÖÃâÒ߯½ºâ״̬£¬ÒÔ¼°»Ö¸´Õý³£ÃâÒßÓ¦´ðµÄÄÜÁ¦¡£ ½üÄêÀ´£¬ÃâÒßµ÷¿ØÏà¹ØµÄÑо¿²ã³ö²»Ç2023ÄêÖбêÊý¸ß´ï985¸ö£¬¿É¼û´ó¼Ò¶ÔÓÚÕâÒ»Ñо¿·½ÏòµÄÈÈÖÔ¡£½ñÌìСÖúÊÖ¸ø´ó¼ÒÕûÀíÁ˼¸Æª½üÄê·¢±íµÄ¸ß·ÖÎÄÕ£¬Óë´ó¼Ò¹²Í¬Ñ§Ï°Ò»ÏÂÃâÒßµ÷¿Ø·½ÏòÓÐÄÄЩеÄÑо¿Ë¼Â·¡£ 1¡¢Cell£¨IF=64.5£©£¬C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection ϵͳÐÔÄîÖé¾ú¸ÐȾÊÇÒ»ÖÖ³£¼ûµÄ¡¢¸ßËÀÍöÂʵÄÒ½ÔºÕæ¾ú¸ÐȾ¡£³öºõÒâÁϵÄÊÇ£¬ËüÒѳÉΪ¿¹²¹ÌåC5°ÐÏòµ¥¿Ë¡¿¹ÌåÖÎÁƵIJ¢·¢Ö¢£¬±íÃ÷C5ÔÚ¿¹Õæ¾úÃâÒßÖоßÓÐÏà¹Ø×÷Óᣱ¾´ÎÑо¿È·¶¨ÁËÔÚÄîÖé¾úѪ֢»¼ÕßÖÐÓÕµ¼µÄ²¹Ìåϵͳ»ùÒòת¼ΪÊ×λµÄÉúÎï;¾¶£¬²¢Ô¤²âÆäÓëÄîÖé¾úѪ֢µÄÏà¹ØÐÔ¡£´Ó»úÖÆÉÏ¿´£¬C5a-C5aR1ͨ¹ý´Ì¼¤ÍÌÊÉϸ°ûЧӦ¹¦ÄÜÒÔ¼°ERKºÍAKTÒÀÀµµÄ¸ÐȾ×éÖ¯´æ»î£¬´Ù½øÐ¡ÊóÈ«ÉíÐÔÄîÖé¾ú²¡Ä£ÐÍÖеÄÕæ¾úÇå³ýºÍËÞÖ÷´æ»î¡£ÇóýC5ar1»ùÒòÖØ¹¹ÁËmTORÏÂÓεľÞÊÉϸ°û´úл£¬´Ù½øÁËËüÃǵĵòÍö£¬²¢Í¨¹ýÉöËðÉËÔö¼ÓÁËËÀÍöÂÊ¡£³ýÁ˸Îϸ°ûÀ´Ô´µÄ C5£¬ÓÉÍÌÊÉϸ°ûÄÚÔ´ÐÔ²úÉúµÄC5ÌṩÁË¿¹Õæ¾ú±£»¤µÄ¹Ø¼üµ×ÎѪÇåµÍC5aŨ¶È»ò¼õÉÙ°×ϸ°û C5±í´ïµÄC5¶à̬ÐÔÓ뻼ÕßÔ¤ºó²»Á¼Ïà¹Ø¡£×ÛÉÏËùÊö£¬¾Ö²¿ÍÌÊÉϸ°û²úÉúµÄC5²úÎïÊÚȨÁËÍÌÊÉϸ°ûµÄ¿¹Î¢ÉúÎ﹦ÄÜ£¬²¢ÔÚÈ«ÉíÕæ¾ú¸ÐȾ¹ý³ÌÖÐÌṩ¹ÌÓб£»¤¡£ 2¡¢Bioactive Materials£¨IF=18.9£©£¬A multifunctional neuromodulation platform utilizing Schwann cell-derived exosomes orchestrates bone microenvironment via immunomodulation, angiogenesis and osteogenesis ×î½üµÄÑо¿Ö¤Ã÷ÁËÔÚ¹ÇÔÙÉúÖÐÖØÏÖ¹Ç΢»·¾³ÖÐµÄ¶à·½ÃæÉúÎïѧÐèÇó¡£Éñ¾»¯¶ÔÓÚʵÏÖ¹Ç×éÖ¯¹¤³Ì£¨BTE£©ÖеĶàϵͳµ÷¿Ø¾ßÓо޴óDZÁ¦¡£È»¶ø£¬ËùÓÐÉæ¼°¹Ø¼ü¹ÇÐÞ¸´²½ÖèµÄÉñ¾²ßÂÔÉÐ䱨µÀ¡£ÔÚ±¾Ñо¿ÖУ¬Éñ¾×éÖ¯¹¤³ÌË®Äý½º·â×°µÄϸ°ûÀ´Ô´ÍâÃÚÌ壨SC Exo£©¡£ÕâÖÖ³ÖÐøÊÍ·ÅµÄ SC Exoϵͳͨ¹ý´Ù½øÌåÄÚµÄÉñ¾»¯¡¢ÃâÒßµ÷½Ú¡¢Ñª¹Ü»¯ºÍ³É¹Ç×÷ÓÃÏÔÖøÔöÇ¿Á˹ÇÔÙÉú¡£´ËÍ⣬ÌåÍâ½á¹û½øÒ»²½È·ÈÏÁ˸ÃϵͳÏÔÖøÓÕµ¼¾ÞÊÉϸ°ûµÄ M2¼«»¯¡¢HUVECsµÄ¹ÜÐγÉÒÔ¼° BMSCsµÄ³É¹Ç·Ö»¯¡£´ËÍ⣬ͨ¹ýÉϵ÷ TGF-¦Â1/SMAD2/3ÐźÅͨ·´Ù½øÁË BMSCsµÄ³É¹Ç¡£×ÛÉÏËùÊö£¬±¾Ñо¿ÖÐ×÷Õ߳ɹ¦¿ª·¢ÁËÒ»ÖÖеÄÎÞϸ°û¡¢Ò×ÓÚÖÆ±¸µÄ SC-ExoÉñ¾¹¤³Ì£¬Í¨¹ýе÷Õû¸ö¹ÇÓúºÏ΢»·¾³À´´Ù½ø¹ÇÔÙÉú£¬Õâ¿ÉÄÜΪ×éÖ¯¹¤³ÌºÍ¹ÇȱËðµÄÁÙ´²ÖÎÁÆÌṩһÖÖвßÂÔ¡£ 3¡¢Immunity£¨IF=32.4£©£¬Restraint of IFN-¦Ã expression through a distal silencer CNS-28 for tissue homeostasis IFN-¦ÃÊDz¸È鶯ÎïÓ¦¶Ô²¡¶¾»òϸ°ûÄÚϸ¾ú¸ÐȾµÄ¹Ø¼üϸ°ûÒò×Ó¡£ËäÈ»Ðí¶àÔöÇ¿×Ó±»ÃèÊöΪ´Ù½øIFN-¦Ã·´Ó¦£¬µ«»¹Ã»Óз¢ÏÖIfng»ùÒòµÄ³ÁĬÒò×Ó¡£Í¨¹ýÔÚIfng»ùÒòλµãÄÚµÄnaive CD4+Tϸ°ûÖмì²éH3K4me1×éµ°°×ÐÞÊΣ¬ÎÒÃǼø¶¨ÁËÒ»¸öÒÖÖÆÒò×Ó£¨CNS-28£©£¬¸ÃÒÖÖÆÒò×ÓÒÖÖÆIfng±í´ï¡£´Ó»úÖÆÉϽ²£¬CNS-28ͨ¹ýÒÔ GATA3ÒÀÀµT-betÒÀÀµµÄ·½Ê½¼õÉÙIfng»ùÒòλµãÄÚµÄÔöÇ¿×Ó-Æô¶¯×ÓÏ໥×÷ÓÃÀ´Î¬³ÖIfng³ÁĬ¡£ÔÚ¹¦ÄÜÉÏ£¬CNS-28ÔÚÏÈÌìÃâÒß·´Ó¦ºÍÊÊÓ¦ÐÔÃâÒß·´Ó¦ÆÚ¼äÒÖÖÆ NK ϸ°û¡¢CD4+ϸ°ûºÍ CD8+Tϸ°ûÖÐµÄ Ifngת¼¡£´ËÍ⣬ÓÉÓÚ IFN-¦Ã ±í´ïÉý¸ß£¬CNS-28 ȱ·¦µ¼ÖÂ2ÐÍ·´Ó¦±»ÒÖÖÆ£¬´Ó¶ø¸Ä±äÁËTh1ºÍTh2µÄģʽ¡£Òò´Ë£¬CNS-28»îÐÔͨ¹ýÓëIfng»ùÒòλµãÄ򵀮äËûµ÷¿ØË³Ê½Ôª¼þºÏ×÷£¬×î´óÏ޶ȵؼõÉÙ×ÔÉíÃâÒߣ¬´Ó¶øÈ·±£ÃâÒßϸ°û¾²Ö¹¡£ 4¡¢Nature Immunology£¨IF=30.5£©£¬Transcription factor EGR2 controls homing and pathogenicity of TH17 cells in the central nervous system TH17¼È±£»¤ÆÁÕÏ×éÖ¯ÓÖ´¥·¢×ÔÉíÃâÒß¡£ÕâЩ¶ÔÁ¢½ø³Ì±³ºóµÄ»úÖÆÉв»Çå³þ¡£±¾Ñо¿Öз¢ÏÖת¼Òò×ÓEGR2¿ØÖÆÖÐÊàÉñ¾ÏµÍ³£¨CNS£©ÖÐÖ²¡ÐÔTH17ϸ°ûµÄת¼³ÌÐò£¬µ«²»¿ØÖÆÆÁÕÏλµãµÄ±£»¤ÐÔTH17µÄת¼³ÌÐò¡£¶à·¢ÐÔÓ²»¯Ö¢»¼ÕߺÍ×ÔÉíÃâÒßÐÔÉñ¾Ñ×֢СÊóµÄËèÇÊ·´Ó¦ÐÔCD4+Tϸ°ûÖÐ EGR2ÏÔÖøÉý¸ß¡£EGR2ת¼³ÌÐò¾²Ä¬±àÖ¯ÔÚTH17ϸ°ûת¼µ÷¿ØÍøÂçÖУ¬²¢ÓëºËÐÄTH17ϸ°ûÌØÒìÐÔת¼Òò×ÓÖ®¼ä¾ßÓеĸ߶Ȼ¥ÁªÐÔ¡£´Ó»úÖÆÉϽ²£¬EGR2ͨ¹ýÉϵ÷Ó벡ÀýÏà¹Ø»ùÒòºÍËèÑùµ¥ºËϸ°ûÇ÷»¯Òò×Ó£¬ÔöÇ¿ TH17ϸ°û·Ö»¯ºÍËèÑùϸ°ûÏòCNSµÄ=¡£Egr2µÄTϸ°ûÌØÒìÐÔÇóýÔÚ²»Ëðº¦ËÞÖ÷¿ØÖƸÐȾÄÜÁ¦µÄÇé¿öϼõÇáÁËÉñ¾Ñ×Ö¢¡£×ÛÉÏËùÊö£¬EGR2ÔÚCNSµÄ²¡ÔÐÔTH17ϸ°ûÖе÷¿Ø×éÖ¯ÌØÒìºÍ¼²²¡ÌØÒ칦ÄÜ¡£ |
» ²ÂÄãϲ»¶
Âé·³¸÷λÀÏʦÓÐHT29-MTXÕâ¸öϸ°ûÖêÂð£¬Óг¥¹ºÂò£¡
ÒѾÓÐ1È˻ظ´
2026É격
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ98È˻ظ´
ºÏ³É
ÒѾÓÐ0È˻ظ´
°±»ùËáµÄõ£»¯·´Ó¦£¬Çó´óÀнâ´ð
ÒѾÓÐ0È˻ظ´
26ÄêÉ격¡ª¡ªÒÑ·¢SCI6ƪ
ÒѾÓÐ13È˻ظ´
¼î¸×µÄÅäÖÆ
ÒѾÓÐ5È˻ظ´
У¡°ÄÃſƼ¼´óѧ³ÏÕÐ2026ÄêÇï¼¾Ò©¼Áѧ/ÉúÎï²ÄÁÏ·½Ïò²©Ê¿Ñо¿Éú£¨ÉêÇë-¿¼ºËÖÆ£©
ÒѾÓÐ18È˻ظ´
°Ä¿Æ´óҩѧԺ³ÏÕÐ2026ÄêÇï¼¾ÄÉÃ×ҽѧ/ÉúÎï²ÄÁϲ©Ê¿Ñо¿Éú
ÒѾÓÐ15È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
³ÏÕ÷ÁíÒ»°ë
+1/192
ºþÄÏʦ·¶´óѧҽ¹¤½»²æ¿ÆÑÐÍŶÓÕÐÊÕ²©Ê¿Ñо¿Éú
+1/174
µ¼µç¸ß·Ö×ÓÓÃʲô¹¤ÒÕ´¦Àí·Ö×ÓÁ´µÄ¶Ñµþ»á¸ü¼Ó¹æÕû£¿£¿£¿
+1/81
ÉϺ£º£Ñó´óѧÓëÖйúË®²ú¿ÆÑ§Ñо¿Ôº ÁªºÏÅàÑø ѧÊõÐÍÑо¿Éú ʳƷ¿ÆÑ§Ó빤³Ìרҵ
+1/76
¹ãÖÝ
+1/70
Õã½Ê¦·¶´óѧÉêÀû¹ú½ÌÊÚÕÐÆ¸²©Ê¿ºóÑо¿ÈËÔ±
+1/29
ôßÄÏ´óѧÀí¹¤Ñ§Ôº ¹â×Ó¼¼ÊõÑо¿Ôº¶ÎÐûÃ÷ÍŶÓÉêÇëÖÆ¶Á²©ÕÐÉú
+1/29
¡¾ÕÐÉúÀ²ÕÐÉúÀ²¡¿Î人Àí¹¤´óѧÖìÂü¸±Ñо¿Ô±ÕÐÊÕ2026Äê9ÔÂÈëѧ²©Ê¿/˶ʿÑо¿Éú
+1/28
ÉîÛÚ´óѧÀîÌìÈβ©Ê¿¿ÎÌâ×éÑо¿ÉúÕÐÉúÐÅÏ¢
+1/26
ÄϿƴóÏĺ£Æ½ÔºÊ¿-Éî´óÕÅÆ½Óñ¿ÎÌâ×éÁªºÏÕÐÆ¸²©Ê¿ºó
+1/26
ÉîÈÝSCIÖÇÄÜÌåËÄ´óÄ£¿é£ºMethod, Introduction, Discussion, Abstract
+1/11
Ìì½ò´óѧ»¯Ñ§ÏµÎâÁ¢Åó¿ÎÌâ×éÉêÇ뿼ºËÖÆ²©Ê¿ÕÐÉú/²©ºóÕÐÆ¸
+1/10
Ìì½ò´óѧ»¯Ñ§ÏµÎâÁ¢Åó¿ÎÌâ×éÉêÇ뿼ºËÖÆ²©Ê¿ÕÐÉú/²©ºóÕÐÆ¸
+1/8
²©Ê¿ÉúÕÐÉú, ÄϾ©´óѧ²ÄÁÏÎïÀí
+1/5
Î人´óѧ¹ùÓîÌÊÚ¿ÎÌâ×éÕÐÊÕ²©Ê¿ºóµÈÑо¿ÈËÔ±¡¾ÏȽø·â×°/оƬ/È˹¤ÖÇÄܵȷ½Ïò¡¿
+1/5
³¤´º¹¤Òµ´óѧ»úµç¹¤³ÌѧԺº«Áá½ÌÊÚÕÐÊÕÉóºËÖÆ2026ÄêÇï¼¾Èëѧ²©Ê¿Éú
+1/5
ÄϾ©ÁÖÒµ´óѧ¡±ÉêÇë-¿¼ºË¡±ÖÆÑ§Êõѧλ²©Ê¿Ñо¿ÉúÕÐÉú
+1/3
ºþÄÏ´óѧ»úеÓëÔËÔØ¹¤³ÌѧԺÕÔÑÒ¸±½ÌÊÚ¿ÎÌâ×éÕÐÉú2026¼¶ÆÕͨ²©Ê¿Éú1Ãû
+1/3
¾¼Ãѧ²©Ê¿£¨½ðÈÚ·½Ïò£©ÕÐÉú£¬211ÖØµã´óѧ£¬2026Äê9ÔÂÈëѧ£¬ÉêÇë-¿¼ºËÖÆ¡£
+1/2
±±¾©Ê¦·¶´óѧÓëÆóÒµÁªºÏÕÐÆ¸²©Ê¿ºó¡¢È«Ö°¡¢¼æÖ°ÈËÔ±
+1/1
6Â¥2024-08-06 16:40:20
¼òµ¥»Ø¸´
tzynew2Â¥
2024-08-06 08:47
»Ø¸´
ÉúÎïҽҩʵÑéÍâ°(½ð±Ò+1): лл²ÎÓë
i ·¢×ÔСľ³æAndroid¿Í»§¶Ë
zusn3Â¥
2024-08-06 10:50
»Ø¸´
nono20094Â¥
2024-08-06 11:57
»Ø¸´
ÉúÎïҽҩʵÑéÍâ°(½ð±Ò+1): лл²ÎÓë
¡¤
tfang5Â¥
2024-08-06 16:00
»Ø¸´
ÉúÎïҽҩʵÑéÍâ°(½ð±Ò+1): лл²ÎÓë
¸ý³½ÐÁ³ó7Â¥
2024-08-06 17:13
»Ø¸´







»Ø¸´´ËÂ¥